Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Santen SAS


1, rue Pierre Fontaine – Building 4
91058 EVRY Cedex – FRANCE
Phone : +33 1 69 87 40 20

Jean-Sébastien GARRIGUE: Research Manager
Web Site >
Santen - Genopole's Company Santen - Genopole's Company

#Health / Well-being #Therapeutics

  • Ophthalmology
  • Technologies
  • Cationorm®

Field of Activity


Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Santen Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.

BACKGROUND

For 120 years now, Santen has been continuing its commitment to improving the eyesight and health of patients across the globe, building upon a spirit of creation, innovation and strong company values.

Santen SAS has been marketing the company’s ophthalmological products in France since 2014. The French company is also a Santen Group Center of Excellence dedicated to innovative ophthalmological R&D for all eye segments.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

Santen SAS has a sales and marketing organization to commercialize pharmaceutical ophthalmic products in France.

In terms of research activities, within Santen we have concentrated our basic research, non-clinical studies, and drug formulation research at Nara R&D Center, so as to integrate the knowledge of our various sections and create better products. In 2011, Santen purchased Novagali Pharma (today Santen S.A.S.), a French ophthalmic pharmaceutical company that has excellent R&D capability and drug formulation technologies in the dry eye field. This purchase has reinforced Santen’s development pipelines, enhancing its international competitiveness in the ophthalmic field.

  • Further Information

    28 patents
    78 staff members (in France)

    Strengths:
    Cationorm®, the first cationic emulsion to treat dry eye symptoms, marketed in more than 50 countries. A portfolio comprising a range of products at various stages of development, particularly the marketed medications Ikervis®, indicated for the treatment of severe keratitis in patients presenting dry eye symptoms, and Verkazia® indicated in severe vernal keratoconjunctivitis in children and adolescents.

    Innovation assets:
    Development of innovative ophthalmological products, patented technologies, bioavailability, tolerability

Share
CompanieGenopole’s Companies

#Health / Well-being


In same field

Vitropep -entreprise genopole

Vitropep

Vitropep developed a unique technology allowing to inject certain peptides without cold chain and with self-administration.

Discover
PEP-Therapy - Genopole's Company - logo 2021

PEP-Therapy

PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Discover
Exosome Analytics - Entreprise génopolitaine

Exosome Analytics

Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.

Discover

bYoRNA

Platform for the bioproduction of RNA through fermentation in eukaryotic cells, a paradigm shift from in vitro synthesis

Discover
Kyron.Bio - Genopole's Company

Kyron.Bio

Kyron.Bio is a biotech company using synthetic biology to produce new therapies with high yield, activity, and stability standards.

Discover
CGenetix - Entreprise génopolitaine

CGenetix

CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.

Discover
EndoGene.Bio - Genopole's Company

EndoGene.Bio

Research & development for an in vitro diagnostic tool for endometriosis

Discover
Exosome Analytics - Entreprise génopolitaine

Exosome Analytics

Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.

Discover
Ciclix - StrokeHub - Genopole's company

Ciclix

Ciclix is a tech driven company specialized in process digitization for hospitals and focused on creating natural and efficient solutions for a variety of user profiles in the hospital environment.

Discover
Echoliv -Genopole's company

ECHOLIV

Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.

Discover
DeepTope - Genopole's company

Deeptope

– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Discover
Theranovir - Genopole's Company

Theranovir

Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases

Discover
Cell Environment - Genopole's company

Cell Environment

Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.

Discover
Innovhem - Entreprise génopolitaine

Innovhem

Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease

Discover
Whitelab Genomics - Genopole's Company

WhiteLab Genomics

Artificial intelligence to optimize and accelerate the development of gene therapies

Discover
Traaser - Genopole's Company

TRaaSer

Software for biomedical data analysis

Discover
Synsight - Genopole's Company

Synsight

Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

Discover
Sebia - Genopole's Company

Sebia

Design, manufacture and commercialization of in vitro diagnostic systems (instruments and reagents) for medical biology laboratories.

Discover
Pharnext - Genopole's company

Pharnext SA

Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).

Discover
IntegraGen - Genopole's Company

Integragen

IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.

Discover
View all >
With the support from
Région île de France